You are here: Industry Insights > servier

News List

Servier Announces FDA Approval of TIBSOVO (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma firstwordpharma
August 26, 2021
Servier Pharmaceuticals announced today that the U.S. Food and Drug Administration approved TIBSOVO®(ivosidenib tablets) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation.
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid prnasia
August 02, 2021
Servier, a global pharmaceutical company, today announced the global Phase 3 double blinded placebo controlled AGILE study of TIBSOVO (ivosidenib tablets) in combination with the chemotherapy azacitidine in adults with previously untreated ...
Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics prnasia
July 13, 2021
Servier announced that they have entered into a strategic collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological diseases.
Servier and PRISM BioLab enter drug discovery collaboration for a novel target firstwordpharma
June 18, 2021
Servier and PRISM BioLab, a Japan based biotechnology company with proprietary small molecule drug discovery platform, “PepMetics™Technology”, today announced that they have entered into a Collaboration and Exclusive License Option Agreement.
Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio contractpharma
April 02, 2021
Servier, a global pharmaceutical company, has successfully completed its acquisition of Agios Pharmaceuticals' commercial, clinical and research-stage oncology portfolio for up to $2 billion plus royalties.
Servier found guilty of deception and manslaughter over deadly weight loss pill pharmaceutical-technology
March 30, 2021
French pharmaceutical company Servier has been found guilty of “aggravated deception” and “manslaughter and involuntary injury” over a drug linked to the deaths of up to 2,000 people.
Servier and MiNA Therapeutics ink neurology pact pharmatimes
January 25, 2021
French pharma company Servier has entered into a research partnership with UK biotech MiNA Therapeutics to develop small activating RNA (saRNA) therapies for the treatment of neurological diseases.
Servier and X-Chem Enter Drug Discovery Collaboration contractpharma
January 08, 2021
Servier, a global pharmaceutical Group, and X-Chem Inc., a privately held drug discovery company, have partnered to identify and develop novel small molecules for the treatment of neurological disorders.
Servier to Acquire Agios Pharmaceuticals' Oncology Business prnasia
December 22, 2020
Servier, a global pharmaceutical company, announced that it has entered into an agreement for the acquisition of Agios Pharmaceuticals' oncology business including its commercial, clinical and research-stage oncology portfolio for up to $2 billion ...
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients prnasia
October 16, 2020
Servier and Galapagos NV report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086.

Previous page 1 2 3 Next page